白三烯受体拮抗剂对儿童急性喘息性支气管炎的疗效研究(1)
[摘要]目的 探討白三烯受体拮抗剂孟鲁司特钠对儿童急性喘息性支气管炎的临床疗效。方法 选取我院2018年1月～2019年6月收治的80例急性喘息性支气管炎患儿，按治疗方式不同分为观察组(40例)与对照组(40例)。对照组行常规治疗，在此基础上，观察组行白三烯受体拮抗剂孟鲁司特钠治疗。比较两组的临床疗效、临床症状缓解时间、喘息再发率、炎性介质、治疗安全性。结果 观察组的治疗总有效率为95.00%，高于对照组的77.50%，差异有统计学意义(P<0.05);观察组治疗后6个月内的喘息再发率为5.00%，低于对照组的25.00%，差异有统计学意义(P<0.05);观察组的喘息缓解时间、哮鸣音消失时间、咳嗽消退时间、住院时间短于对照组，白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平低于对照组，差异有统计学意义(P<0.05);两组治疗期间的不良反应总发生率比较，差异无统计学意义(P>0.05)。结论 急性喘息性支气管炎患儿接受白三烯受体拮抗剂孟鲁司特钠治疗可有效提高临床效果，促进临床症状缓解，改善炎性反应，减少喘息再发，安全性较高。
[关键词]急性喘息性支气管炎;白三烯受体拮抗剂;炎性反应;孟鲁司特钠;安全性
[中图分类号] R725.6 [文献标识码] A [文章编号] 1674-4721(2020)7(c)-0103-03
Clinical efficacy study of Montelukast Sodium of leukotriene receptor antagonist on acute asthmatic bronchitis in children
WU Zhuo-jian1 ZHONG Mei-gong1 TAN Wen-qiang1 LI Jun-wen2 XU Jie2 LIANG Fa-liang1 FENG Yue-hua1
1. Department of Pharmacy， Jiangmen Maternal and Child Health Hospital， Guangdong Province， Jiangmen 529000， China; 2. Department of Pediatrics， Jiangmen Maternal and Child Health Hospital， Guangdong Province， Jiangmen 529000， China
[Abstract] Objective To investigate the clinical efficacy of Montelukast Sodium of leukotriene receptor antagonist on children with acute asthmatic bronchitis. Methods A total of 80 children with acute asthmatic bronchitis admitted to our hospital from January 2018 to June 2019 were selected and divided into the observation group (40 cases) and the control group (40 cases) according to the different treatment methods. The control group was treated with routine treatment， the observation group was treated with Montelukast Sodium of leukotriene receptor antagonist on this basis. The clinical efficacy， the time of clinical symptom relief， the recurrence rate of wheezing， inflammatory mediators and the safety of treatment were compared between the two groups. Results The total effective rate of the observation group was 95.00%， which was higher than that of the control group (77.50%)， the difference was statistically significant (P<0.05). The recurrence rate of wheezing was 5.00% in the observation group within 6 months after treatment， which was lower than 25.00% in the control group， the difference was statistically significant (P<0.05). The wheezing relief time， wheezing disappeared time， cough subsided time and hospitalization time in the observation group were shorter than those in the control group， the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) of the observation group were lower than those of the control group， the differences were statistically significant (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion The treatment of Montelukast Sodium of leukotriene receptor antagonists in children with acute asthmatic bronchitis can effectively improve the clinical efficacy， promote the relief of clinical symptoms， improve the inflammatory response， reduce the recurrence of asthma， and have a high safety., 百拇医药(伍卓坚 钟媚共 谭文锵 李军文 徐杰 梁法亮 冯月华)
[关键词]急性喘息性支气管炎;白三烯受体拮抗剂;炎性反应;孟鲁司特钠;安全性
[中图分类号] R725.6 [文献标识码] A [文章编号] 1674-4721(2020)7(c)-0103-03
Clinical efficacy study of Montelukast Sodium of leukotriene receptor antagonist on acute asthmatic bronchitis in children
WU Zhuo-jian1 ZHONG Mei-gong1 TAN Wen-qiang1 LI Jun-wen2 XU Jie2 LIANG Fa-liang1 FENG Yue-hua1
1. Department of Pharmacy， Jiangmen Maternal and Child Health Hospital， Guangdong Province， Jiangmen 529000， China; 2. Department of Pediatrics， Jiangmen Maternal and Child Health Hospital， Guangdong Province， Jiangmen 529000， China
[Abstract] Objective To investigate the clinical efficacy of Montelukast Sodium of leukotriene receptor antagonist on children with acute asthmatic bronchitis. Methods A total of 80 children with acute asthmatic bronchitis admitted to our hospital from January 2018 to June 2019 were selected and divided into the observation group (40 cases) and the control group (40 cases) according to the different treatment methods. The control group was treated with routine treatment， the observation group was treated with Montelukast Sodium of leukotriene receptor antagonist on this basis. The clinical efficacy， the time of clinical symptom relief， the recurrence rate of wheezing， inflammatory mediators and the safety of treatment were compared between the two groups. Results The total effective rate of the observation group was 95.00%， which was higher than that of the control group (77.50%)， the difference was statistically significant (P<0.05). The recurrence rate of wheezing was 5.00% in the observation group within 6 months after treatment， which was lower than 25.00% in the control group， the difference was statistically significant (P<0.05). The wheezing relief time， wheezing disappeared time， cough subsided time and hospitalization time in the observation group were shorter than those in the control group， the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) of the observation group were lower than those of the control group， the differences were statistically significant (P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups (P>0.05). Conclusion The treatment of Montelukast Sodium of leukotriene receptor antagonists in children with acute asthmatic bronchitis can effectively improve the clinical efficacy， promote the relief of clinical symptoms， improve the inflammatory response， reduce the recurrence of asthma， and have a high safety., 百拇医药(伍卓坚 钟媚共 谭文锵 李军文 徐杰 梁法亮 冯月华)